These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 12533265)

  • 1. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
    J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
    Park SH; Cho EK; Bang SM; Shin DB; Lee JH; Lee YD
    BMC Cancer; 2005 Feb; 5():21. PubMed ID: 15723709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
    Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
    Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
    Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
    Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
    Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
    Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.